Benefit of adding low molecular weight heparin to the conventional treatment of stable angina pectoris. A double-blind, randomized, placebo-controlled trial.

Melandri, G; Semprini, F; Cervi, V; Candiotti, N; Palazzini, E; Branzi, A; Magnani, B

Melandri, G; Semprini, F; Cervi, V; Candiotti, N; Palazzini, E; Branzi, A; Magnani, B.

Affiliation

Melandri G; Institute of Cardiology, University of Bologna, Italy.

Circulation ; 88(6): 2517-23, 1993 Dec.

Article in En | MEDLINE | ID: mdl-8252662

Subject(s)

Angina Pectoris/drug therapy; Heparin, Low-Molecular-Weight/administration & dosage; Adult; Aged; Angina Pectoris/blood; Angina Pectoris/physiopathology; Bleeding Time; Cardiovascular Agents/administration & dosage; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Female; Fibrinogen/metabolism; Humans; In Vitro Techniques; Male; Middle Aged; Platelet Aggregation/drug effects

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Heparin, Low-Molecular-Weight / Angina Pectoris Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Circulation Year: 1993 Type: Article Affiliation country: Italy

Search on Google

XML

PubMed Links